LUXExperience BV is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who is unwilling to wait for a better entry. The stock is trading in a weak technical position, has no bullish proprietary buy signal today, and the latest setup suggests further downside is more likely than an immediate rebound. I would not buy it at this moment.
The chart setup is bearish. MACD histogram is negative at -0.119 and still contracting, which shows downside momentum is not yet exhausted. RSI_6 at 30.635 is near oversold territory but still neutral, so it does not yet confirm a reversal. Moving averages are bearish with SMA_200 > SMA_20 > SMA_5, confirming a downtrend across multiple timeframes. Price is currently around 6.80-6.94, below the pivot at 7.256 and only slightly above support at S1 6.694, leaving limited upside until it can reclaim resistance. The modeled trend also points lower, with a 70% chance of -0.7% next day, -3.13% next week, and -6.41% next month.

["TD Cowen kept a Buy rating and highlighted continued strength at Mytheresa.", "Q3 sales grew 9.9%, driven by 18.6% top customer growth and 12.5% AOV growth, showing healthy demand quality.", "Option volume today is tilted toward calls versus puts, which is a mild short-term supportive sign."]
["No news in the recent week, so there is no fresh event-driven catalyst.", "JPMorgan lowered its price target to $9 from $10 and keeps only a Neutral rating.", "TD Cowen also lowered its target to $8 from $12, so analyst enthusiasm is softening even with a Buy rating maintained.", "No recent insider buying, hedge fund accumulation, or congress trading activity was reported.", "Technical trend remains bearish and nearby downside targets are closer than upside targets."]
Latest financial snapshot data was unavailable due to an error, so only the commentary from analysts can be used. The most recent quarterly reference is Q3, where sales increased 9.9% year over year, driven by stronger customer growth and higher average order value. That indicates healthy top-line momentum, but the lack of full financial details limits confidence in the current investment case.
Analyst sentiment is mixed to slightly cautious. TD Cowen lowered its price target to $8 from $12 but maintained a Buy rating after Q3 results, while JPMorgan cut its target to $9 from $10 and kept a Neutral rating. The pros view is that operating momentum at Mytheresa remains strong, especially in customer growth and AOV. The cons view is that price targets are being reduced and the Street is not broadly turning more bullish, which suggests limited near-term conviction.